With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more
NVO is expected to report earnings to rise 3.12% to 95 cents per share on November 05
Q3'25
Est.
$0.96
Q2'25
Est.
$0.93
Q1'25
Beat
by $5.64
Q4'24
Beat
by $5.46
Q3'24
Beat
by $5.24
The last earnings report on August 06 showed earnings per share of 92 cents, missing the estimate of 93 cents. With 1.71M shares outstanding, the current market capitalization sits at 224.52B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. NVO showed earnings on August 06, 2025. You can read more about the earnings report here.